Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to Illumina stockholders1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 17, 2021 | = | ÷ | = | ÷ | |||||||
Feb 11, 2020 | = | ÷ | = | ÷ | |||||||
Feb 12, 2019 | = | ÷ | = | ÷ | |||||||
Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
Mar 2, 2016 | = | ÷ | = | ÷ | |||||||
Feb 18, 2015 | = | ÷ | = | ÷ | |||||||
Feb 18, 2014 | = | ÷ | = | ÷ | |||||||
Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
Feb 26, 2008 | = | ÷ | = | ÷ | |||||||
Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
Mar 6, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Illumina Inc. Annual Report.
The analysis of the financial data over the examined period reveals several notable trends in the share price, earnings per share (EPS), and price-to-earnings (P/E) ratio of the company.
- Share Price
-
The share price experienced significant growth from 12.79 US$ in March 2006 to 494.24 US$ in February 2021. This represents a substantial increase over the 15-year span. The price showed notable volatility, including periods of sharp increase, such as between 2013 and 2015 when the price rose from 48.73 US$ to 198.62 US$, and again from 2018 to 2021, surging from 220.44 US$ to nearly 500 US$. Despite occasional declines, the overall trajectory of the share price was upward, reflecting strong market confidence or growth expectations.
- Earnings Per Share (EPS)
-
The EPS demonstrated variability, starting with a negative value of -0.25 US$ in 2006 and moving through fluctuations including another negative period in 2008 (-2.51 US$). Following this, EPS generally trended upward, reaching a peak of 6.82 US$ in 2020 before declining to 4.5 US$ in 2021. The pattern indicates periods of operational challenges in the earlier years but a consistent improvement in profitability or earnings generation capability over time. The dip in the final year measured may reflect specific short-term issues or market conditions affecting earnings.
- Price-to-Earnings (P/E) Ratio
-
The P/E ratio showed considerable fluctuation, indicating varied market valuation sentiments relative to earnings. Some years reported extremely high P/E ratios, such as 174.33 in 2014 and 109.92 in 2021, suggesting the market anticipated strong future growth or that earnings were temporarily low relative to the share price. Years with missing P/E values correspond to periods of negative EPS, making the P/E calculation invalid. The overall trend shows that the market often valued the company at a premium, consistent with the growth dynamics suggested by the share price and EPS trends.
In summary, the financial data reflect a company that transitioned from early earnings difficulties to sustained profitability and significant appreciation in share price. The high P/E ratios across multiple years imply strong market expectations for future performance, although the volatility in EPS and occasional declines in share price indicate some operational or market risks. The decline in EPS in the latest reported year suggests close monitoring is warranted to understand underlying causes and potential future impacts on valuation and profitability.
Comparison to Competitors
Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 17, 2021 | |||||||||||||
Feb 11, 2020 | |||||||||||||
Feb 12, 2019 | |||||||||||||
Feb 13, 2018 | |||||||||||||
Feb 14, 2017 | |||||||||||||
Mar 2, 2016 | |||||||||||||
Feb 18, 2015 | |||||||||||||
Feb 18, 2014 | |||||||||||||
Feb 15, 2013 | |||||||||||||
Feb 24, 2012 | |||||||||||||
Feb 28, 2011 | |||||||||||||
Feb 26, 2010 | |||||||||||||
Feb 26, 2009 | |||||||||||||
Feb 26, 2008 | |||||||||||||
Feb 28, 2007 | |||||||||||||
Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 17, 2021 | ||
Feb 11, 2020 | ||
Feb 12, 2019 | ||
Feb 13, 2018 | ||
Feb 14, 2017 | ||
Mar 2, 2016 | ||
Feb 18, 2015 | ||
Feb 18, 2014 | ||
Feb 15, 2013 | ||
Feb 24, 2012 | ||
Feb 28, 2011 | ||
Feb 26, 2010 | ||
Feb 26, 2009 | ||
Feb 26, 2008 | ||
Feb 28, 2007 | ||
Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc. | Health Care | |
---|---|---|
Feb 17, 2021 | ||
Feb 11, 2020 | ||
Feb 12, 2019 | ||
Feb 13, 2018 | ||
Feb 14, 2017 | ||
Mar 2, 2016 | ||
Feb 18, 2015 | ||
Feb 18, 2014 | ||
Feb 15, 2013 | ||
Feb 24, 2012 | ||
Feb 28, 2011 | ||
Feb 26, 2010 | ||
Feb 26, 2009 | ||
Feb 26, 2008 | ||
Feb 28, 2007 | ||
Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).